Nuvectis Pharma (NVCT)
NASDAQ:NVCT
Want to see NVCT full AI Analyst Report?
NVCT Stock Chart & Stats
$8.90
-$0.26(-4.17%)
At close: 4:00 PM EST
$8.90
-$0.26(-4.17%)
Day’s Range― - ―
52-Week Range$5.55 - $13.34
Previous CloseN/A
Volume31.37K
Average Volume (3M)89.48K
Market Cap
$284.09M
Enterprise Value$233.49M
Total Cash (Recent Filing)$25.13M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.00
Next Earnings
Aug 11, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding26,525,534
10 Day Avg. Volume112,705
30 Day Avg. Volume89,483
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)8.94
Price to Sales (P/S)0.00
P/FCF Ratio-10.29
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.32
Forecast
1Y Price Target
$15.00Price Target Upside68.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.27
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero total debt and positive equity (~$14.2M TTM) materially reduce leverage risk and preserve financial flexibility. Over the next 2–6 months this structural strength supports continued R&D spending, potential partner negotiations, and lowers the probability of forced distress financing versus debt-heavy peers.
Focused Precision Oncology PipelineA clear strategic focus on precision oncology and small-molecule candidates creates durable R&D concentration, improves operational clarity, and enhances attractiveness to strategic partners or acquirers. Specialized pipelines can yield higher-value collaborations and more predictable resource allocation over months ahead.
Governance ContinuityRecent director election and auditor ratification provide continuity in oversight and financial reporting. Stable governance reduces execution and compliance risk, supporting credibility with investors and potential partners, and aids reliable access to capital or collaborations over the medium term.
Bears Say
Pre-revenue With Widening LossesZero product revenue and materially wider net losses create a structural funding gap: operations are entirely financed externally until commercialization. Over 2–6 months, continued negative profitability constrains reinvestment ability and increases execution risk absent near-term program milestones or financing.
High Cash Burn And Negative Cash GenerationSustained negative operating and free cash flow (~-$18.3M TTM) and accelerating burn are a durable constraint on operations. Unless burn is reduced or new financing secured, the company may need to reprioritize programs, slow timelines, or dilute shareholders within the next few quarters.
Reliance On External FinancingAs a development-stage biotech with no recurring commercial revenue, the company structurally depends on equity or other financings. This reliance increases dilution risk and can influence strategic choices, potentially constraining long-term value creation unless clear financing or partnership paths materialize.
Nuvectis Pharma News
NVCT FAQ
What was Nuvectis Pharma’s price range in the past 12 months?
Nuvectis Pharma lowest stock price was $5.55 and its highest was $13.34 in the past 12 months.
What is Nuvectis Pharma’s market cap?
Nuvectis Pharma’s market cap is $284.09M.
When is Nuvectis Pharma’s upcoming earnings report date?
Nuvectis Pharma’s upcoming earnings report date is Aug 11, 2026 which is in 57 days.
How were Nuvectis Pharma’s earnings last quarter?
Nuvectis Pharma released its earnings results on May 05, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.314 by $0.054.
Is Nuvectis Pharma overvalued?
According to Wall Street analysts Nuvectis Pharma’s price is currently Undervalued.
Does Nuvectis Pharma pay dividends?
Nuvectis Pharma does not currently pay dividends.
What is Nuvectis Pharma’s EPS estimate?
Nuvectis Pharma’s EPS estimate is -0.26.
How many shares outstanding does Nuvectis Pharma have?
Nuvectis Pharma has 26,525,534 shares outstanding.
What happened to Nuvectis Pharma’s price movement after its last earnings report?
Nuvectis Pharma reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.314. Following the earnings report the stock price went up 9.224%.
Which hedge fund is a major shareholder of Nuvectis Pharma?
Currently, no hedge funds are holding shares in NVCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nuvectis Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (68.54% Upside)
$15.00 (68.54% Upside)
Blogger Sentiment
Bearish
NVCT Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
82.74%
12-Months-Change
Fundamentals
Return on Equity
-147.78%
Trailing 12-Months
Asset Growth
-15.76%
Trailing 12-Months
Company Description
Nuvectis Pharma
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.
NVCT Stock 12 Month Forecast
Average Price Target
$15.00
▲(68.54% Upside)
Technical Analysis
Nkarta
―
Orchestra BioMed Holdings
―
Greenwich LifeSciences
―
Molecular Partners
―
Pyxis Oncology
―
Ownership Overview
42.55% Insiders
4.41% Mutual Funds
5.94% Other Institutional Investors
42.22% Public Companies and
Individual Investors